Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 2;32(1):17-23.
doi: 10.1097/QAD.0000000000001671.

Benefits and risks of rapid initiation of antiretroviral therapy

Nathan Ford  1   2 , Chantal Migone  1 , Alexandra Calmy  3 , Bernhard Kerschberger  4 , Steve Kanters  5 , Sabin Nsanzimana  6   7 , Edward J Mills  8 , Graeme Meintjes  9 , Marco Vitoria  1 , Meg Doherty  1 , Zara Shubber  10
Affiliations

Benefits and risks of rapid initiation of antiretroviral therapy

Nathan Ford et al. AIDS. .

Abstract

Background: Recent attention has focused on the question of how quickly antiretroviral therapy (ART) should be started once HIV diagnosis is confirmed. We assessed whether rapid ART initiation improves patient outcomes.

Methods: We searched five databases from inception up to August 2017. Rapid ART initiation was defined as initiation within 14 days of HIV diagnosis. Data were pooled using random effects meta-analysis.

Results: Across the randomized trials, ART start on the same day increased viral suppression at 12 months [three trials: relative risk (RR) 1.17, 95% confidence interval (CI) 1.07-1.27], retention in care at 12 months (RR 1.11, 95% CI 0.99-1.26), and the likelihood of starting ART within 90 days (four trials: RR 1.35, 95% CI 1.13-1.62) and 12 months after eligibility was established (three trials: RR 1.17, 95% CI 1.07-1.27). There was a nonsignificant trend toward reduced mortality (three trials: RR 0.53, 95% CI 0.24-1.08), as well as reduced loss to follow-up at 12 months (2 trials: RR 0.66, 95% CI 0.42-1.04). In the observational studies, offering accelerated ART initiation resulted in a greater likelihood of having started ART within 3 months (two studies: RR 1.53, 95% CI 1.11-2.10). There was a trend toward an increased risk of being lost to follow-up at 6 months (three studies: RR 1.85, 95% CI 0.96-3.55).

Conclusion: Accelerated ART initiation can lead to improved clinical outcomes and is likely to be of particular benefit in those settings where extensive patient preparation prior to starting ART results in long delays. These findings informed a WHO recommendation supporting accelerated ART initiation, including same day ART start.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study selection process.
Fig. 2
Fig. 2
Outcomes from randomized trials comparing same day ART start vs standard of care.
See this image and copyright information in PMC

References

    1. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795–807. - PMC - PubMed
    1. Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, Ouassa T, et al. TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808–822. - PubMed
    1. Doherty M, Beusenberg M, Babovic T, et al. Uptake and implementation of the WHO 2015 consolidated ARV guidelines: progress towards treat all. [Abstract THPEB057]. IAS Durban. 21st International AIDS Conference, Durban, July 18–22, 2016
    1. Geng EH, Havlir DV. The science of rapid start: from the when to the how of antiretroviral initiation. PLoS Med 2017; 14:e1002358. - PMC - PubMed
    1. Fox RC, Goemaere E. They call it ‘patient selection’ in Khayelitsha: the experience of Medecins Sans Frontieres-South Africa in enrolling patients to receive antiretroviral treatment for HIV/AIDS. Camb Q Healthc Ethics 2006; 15:302–312. - PubMed

Substances